SecBot SecBot
144 ·Filed Nov 3, 2026

FATE

FATE THERAPEUTICS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed13d 10h ago SEC0001959173-26-007696
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine tax-withholding sale tied to equity vesting, not a discretionary insider disposition. No further insider sales are signaled. Monitor for any larger insider filings (Form 4) that might indicate a change in sentiment.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$2.04
T+0 close · Nov 3, 2026 · via day close
Latest settled
−13.24%
T+5 · $1.77 · next T+20 in 15d
Vs SPY
−12.65%
α at T+5
Latest observation
−41.85%
T+9 · FF3 residual α
  1. T+0 · Nov 3 $2.04entry
  2. T+1 · 13d ago +2.45%α +0.80% · $2.09
  3. T+5 · 7d ago −13.24%α −12.65% · $1.77
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kamal Adawi, an officer of Fate Therapeutics, filed a Form 144 notice of intent to sell 6,582 shares of common stock, valued at approximately $13,525. The sale is to cover a tax obligation from the settlement of a vested equity award. The filing is a routine, small insider sale related to tax withholding and carries no material directional signal.

Key Facts

  • Insider Kamal Adawi (Officer) filed Form 144 to sell 6,582 shares of Fate Therapeutics common stock.
  • The approximate market value of the proposed sale is $13,524.69.
  • The sale is to cover a tax obligation from the settlement of a vested equity award.
  • The proposed sale date is November 3, 2026.
  • The shares were acquired on November 2, 2026 via restricted stock vesting from the issuer.

Financial Impact

Proceeds of approximately $13,525, representing a de minimis fraction of the officer's likely holdings and less than 0.01% of the company's $260M market cap.

dilution

Risk Factors

  • None material from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
61% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-007696
Document: 0001959173-26-007696-index.html0001959173-26-007696
Document: 0001959173-26-007696.txt0001959173-26-007696

Track record

21 reports on FATE

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  2. Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  3. Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
  4. Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
  5. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  6. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  7. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  8. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
  9. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
  10. Nov 3, 202613d ago 144 Neutral 2/10 Viewing Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 7h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026